HRP20220952T1 - Liposomalna formulacija za korištenje kod liječenja raka - Google Patents
Liposomalna formulacija za korištenje kod liječenja raka Download PDFInfo
- Publication number
- HRP20220952T1 HRP20220952T1 HRP20220952TT HRP20220952T HRP20220952T1 HR P20220952 T1 HRP20220952 T1 HR P20220952T1 HR P20220952T T HRP20220952T T HR P20220952TT HR P20220952 T HRP20220952 T HR P20220952T HR P20220952 T1 HRP20220952 T1 HR P20220952T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- glycero
- sodium
- stabilizer
- phospholipid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 14
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 12
- 239000012141 concentrate Substances 0.000 claims 12
- 150000003904 phospholipids Chemical class 0.000 claims 12
- 239000003381 stabilizer Substances 0.000 claims 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 7
- 159000000000 sodium salts Chemical class 0.000 claims 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 229940126062 Compound A Drugs 0.000 claims 5
- 235000010469 Glycine max Nutrition 0.000 claims 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- -1 POPG sodium salts Chemical class 0.000 claims 4
- 150000003863 ammonium salts Chemical class 0.000 claims 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 4
- 235000013601 eggs Nutrition 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- BPHQZTVXXXJVHI-IADGFXSZSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-IADGFXSZSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000008344 egg yolk phospholipid Substances 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 239000000787 lecithin Substances 0.000 claims 3
- 235000010445 lecithin Nutrition 0.000 claims 3
- 229940067606 lecithin Drugs 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000008347 soybean phospholipid Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 2
- PKYIMGFMRFVOMB-UHFFFAOYSA-N 2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid Chemical compound ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C PKYIMGFMRFVOMB-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 claims 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 1
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- QLNOOKSBAYIHQI-SKZICHJRSA-M sodium;2,3-dihydroxypropyl [(2r)-2,3-di(tetradecanoyloxy)propyl] phosphate Chemical group [Na+].CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC QLNOOKSBAYIHQI-SKZICHJRSA-M 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (27)
1. Organski sastav koncentrata koji obuhvaća:
a. Spoj A koji je 2-{[5-{3-kloro-2-metil-4-[2-(4-metilpiperazin-1-il)etoksi]fenil}-6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oksi}-3-(2-{[2-(2-metoksifenil)pirimidin-4-il]metoksi}fenil)propanska kiselina, ili farmaceutski prihvatljiva sol istog,
b. negativno nabijen ili polaran stabilizator fosfolipida, i
c. stabilizator protiv geliranja, pri čemu je stabilizator protiv geliranja polimer odabran od PEG300 i PEG400, ili elektrolit, koji je natrijev klorid.
2. Organski sastav koncentrata u skladu s patentnim zahtjevom 1, koji obuhvaća Spoj A koji je (2R)-2-{[(5Sa)-5-{3-kloro-2-metil-4-[2-(4-metilpiperazin-1-il)etoksi]fenil}-6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oksi}-3-(2-{[2-(2-metoksifenil)pirimidin-4-il]metoksi}fenil)propanska kiselina, ili farmaceutski prihvatljiva sol istog.
3. Organski sastav koncentrata u skladu s patentnim zahtjevima 1 ili 2, pri čemu je Spoj A slobodna molekula.
4. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu je negativno nabijen ili polaran stabilizator fosfolipida odabran od DMPG natrijeve ili amonijeve soli (1,2-Dimiristoil-sn-glicero-3-fosfo-rac-glicerol, ili dimiristoil fosfatidilglicerol), POPG natrijeve soli (1-Palmitoil-2-oleoil-sn-glicero-3 [Fosfo-rac-(1-glicerol)]), DOPS natrijeve soli (1,2-Dioleoil-sn-glicero-3-fosfoserin), DOPG natrijeve soli (1,2-Dioleoil-sn-glicero-3[Fosfo-rac-(1-glicerol)]), DPPG (1,2-Dipalmitoil-sn-glicero-3[Fosfo-rac-(1-glicerol)]) natrijeva ili amonijeva sol, DSPG (1,2-Distearoil-sn-glicero-3[Fosfo-rac-(1-glicerol)]) natrijeva ili amonijeva sol, fosfatne kiseline iz soje (PA) natrijeve soli, fosfatne kiseline iz jaja (PA) natrijeve soli, fosfatidilserina iz soje (PS) natrijeve soli, fosfatidilglicerola iz jaja (PG) natrijeve soli, fosfatidilglicerola iz soje (PG) natrijeve soli, fosfatidil inositol (PI) natrijeve soli, lecitin iz jaja (na primjer Lipoid E 80 S), lecitin iz soje (na primjer Lipoid S 75), i natrijev oleat.
5. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu je negativno nabijen ili polaran stabilizator fosfolipida 1,2-Dimiristoil-sn-glicero-3-fosfo-rac-glicerol, natrijeva ili amonijeva sol, lecitin iz jaja (na primjer Lipoid E 80 S), lecitin iz soje (na primjer Lipoid S 75), poželjno 1,2-Dimiristoil-sn-glicero-3-fosfo-rac-glicerol, natrijeva sol.
6. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je stabilizator protiv geliranja natrijev klorid.
7. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je stabilizator protiv geliranja PEG300.
8. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 7, dalje obuhvaćajući otapalo.
9. Organski sastav koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 8, dalje obuhvaćajući otapalo koje je odabrano od propilen glikola i etanola, ili posebice obuhvaća oboje propilen glikol i etanol.
10. Farmaceutski sastav koji proizlazi iz mješavine organskog sastava koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i liposomskog nosača, pri čemu taj liposomski nosač sadrži fosfolipid i sredstvo za prilagodbu toničnosti odabrano od dekstroze, glukoze, manitola, sukroze, laktoze, trehaloze, glicerina i NaCl.
11. Farmaceutski sastav kao što je naveden u patentnom zahtjevu 10, pri čemu je fosfolipid odabran od lecitina iz jaja, lecitina iz soje, ili sintetičkih fosfolipida.
12. Farmaceutski sastav kao što je naveden u patentnom zahtjevu 10 ili 11, pri čemu je fosfolipid formule
[image]
pri čemu
• R1 predstavlja C10-C24 acil;
• R2 predstavlja C10-C24 acil;
• R3 predstavlja vodik, 2-trimetilamino-1-etil, 2-amino-1-etil, C1-C4 alkil, C1-C5 alkil supstituiran s karboksi, C2-C5 alkil supstituiran s karboksi i hidroksi, C2-C5 alkil supstituiran s karboksi i amino, inozitolnu skupinu ili glicerilnu skupinu;
ili sol takvog spoja.
13. Farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 10 do 12, pri čemu je fosfolipid odabran od lecitina iz jaja, lecitina iz soje, POPC (palmitoil oleoil fosfatidilkolin), DOPC (1,2-Dioleoil-sn-glicero-3-fosfokolin), i DMPC (1,2-Dimiristoil-sn-glicero-3-fosfokolin), posebice POPC (palmitoil oleoil fosfatidilkolin), DOPC (1,2-Dioleoil-sn-glicero-3-fosfokolin), i DMPC (1,2-Dimiristoil-sn-glicero-3-fosfokolin), osobito POPC.
14. Farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 10, 11 ili 13, pri čemu je fosfolipid odabran od lecitina iz jaja ili lecitina iz soje koji obuhvaćaju barem 70% fosfatidilkolina, i osobito odabran od Lipoid E 80 S.
15. Farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 10 do 14, pri čemu je sredstvo za prilagodbu toničnosti odabrano od sukroze ili glicerina.
16. Liposomalni farmaceutski sastav koji sadrži, dodatno uz liposome:
a. Spoj A koji je 2-{[5-{3-kloro-2-metil-4-[2-(4-metilpiperazin-1-il)etoksi]fenil}-6-(4-fluorofenil)tieno[2,3-d]pirimidin-4-il]oksi}-3-(2-{[2-(2-metoksifenil)pirimidin-4-il]metoksi}fenil)propanska kiselina, ili farmaceutski prihvatljiva sol istog,
b. stabilizator protiv geliranja, pri čemu je stabilizator protiv geliranja polimer odabran od PEG300 i PEG400, ili elektrolit koji je natrijev klorid; i
c. negativno nabijen ili polaran stabilizator fosfolipida.
17. Liposomalni farmaceutski sastav kao što je naveden u patentnom zahtjevu 16, koji obuhvaća:
a. Spoj A kao opisan u patentnim zahtjevima 2 ili 3, i
b. stabilizator protiv geliranja, kao opisan u bilo kojem od zahtjeva 6 ili 7.
18. Liposomalni farmaceutski sastav kao što je naveden u patentnom zahtjevu 16, pri čemu je navedeni negativno nabijen ili polaran stabilizator fosfolipida kao opisan u patentnim zahtjevima 4 ili 5.
19. Liposomalni farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 16 do 18, dalje obuhvaćajući otapalo.
20. Liposomalni farmaceutski sastav kao što je naveden u patentnom zahtjevu 19, pri čemu je navedeno otapalo odabrano od propilen glikola i etanola, ili posebice obuhvaća oboje propilen glikol i etanol.
21. Liposomalni farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 16 do 20, obuhvaćajući fosfolipid kao opisan u bilo kojem od patentnih zahtjeva 11 do 14.
22. Liposomalni farmaceutski sastav kao što je naveden u bilo kojem od patentnih zahtjeva 16 do 21, dalje obuhvaćajući sredstvo za prilagodbu toničnosti odabrano od dekstroze, glukoze, manitola, sukroze, laktoze, trehaloze, glicerina i NaCl.
23. Farmaceutski sastav u skladu s bilo kojim od patentnih zahtjeva 10 do 22, za korištenje kao lijek.
24. Farmaceutski sastav za korištenje u skladu s patentnim zahtjevom 23, pri čemu je navedeno korištenje kod liječenja raka, osobitno kad je rak odabran od rakova mjehura, mozga, dojke i maternice, kroničnih limfoidnih leukemija, raka crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutne mijeloične leukemije, limfoma, primjerice ne-Hodgkinovog B-staničnog limfoma i difuznog B-velikostaničnog limfoma, melanoma, malignih hemopatija, primjerice mijelodisplastičnog sindroma, mijeloma, primjerice multiplog mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
25. Uporaba organskog sastava koncentrata u skladu s bilo kojim od patentnih zahtjeva 1 do 9, za pripremu lijeka za liječenje raka.
26. Kombinacija koja sadrži:
a. farmaceutski sastav prema bilo kojem od patentnih zahtjeva 10 do 22, i
b. jedno ili više terapeutski aktivnih sredstava za istovremenu, uzastopnu ili odvojenu uporabu.
27. Komplet koji sadrži:
a. liposomski nosač i
b. organski sastav koncentrata prema bilo kojem od patentnih zahtjeva 1 do 9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306415 | 2016-10-28 | ||
| EP17787939.2A EP3532067B1 (en) | 2016-10-28 | 2017-10-27 | Liposomal formulation for use in the treatment of cancer |
| PCT/EP2017/077538 WO2018078064A1 (en) | 2016-10-28 | 2017-10-27 | Liposomal formulation for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220952T1 true HRP20220952T1 (hr) | 2022-10-28 |
Family
ID=57288337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220952TT HRP20220952T1 (hr) | 2016-10-28 | 2017-10-27 | Liposomalna formulacija za korištenje kod liječenja raka |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10722466B2 (hr) |
| EP (1) | EP3532067B1 (hr) |
| JP (1) | JP7041676B2 (hr) |
| KR (1) | KR102653436B1 (hr) |
| CN (1) | CN109922808B (hr) |
| AR (1) | AR109981A1 (hr) |
| AU (1) | AU2017350499B2 (hr) |
| BR (1) | BR112019008263A2 (hr) |
| CA (1) | CA3041592C (hr) |
| CO (1) | CO2019004190A2 (hr) |
| CU (1) | CU20190046A7 (hr) |
| DK (1) | DK3532067T3 (hr) |
| EA (1) | EA201991025A1 (hr) |
| ES (1) | ES2923929T3 (hr) |
| GE (1) | GEP20217244B (hr) |
| HR (1) | HRP20220952T1 (hr) |
| HU (1) | HUE059448T2 (hr) |
| IL (1) | IL266198B2 (hr) |
| LT (1) | LT3532067T (hr) |
| MA (1) | MA46608B1 (hr) |
| MD (1) | MD3532067T2 (hr) |
| MX (1) | MX2019004941A (hr) |
| MY (1) | MY194730A (hr) |
| PH (1) | PH12019500804A1 (hr) |
| PL (1) | PL3532067T3 (hr) |
| PT (1) | PT3532067T (hr) |
| RS (1) | RS63400B1 (hr) |
| RU (1) | RU2756755C2 (hr) |
| SG (1) | SG11201903326RA (hr) |
| SI (1) | SI3532067T1 (hr) |
| TN (1) | TN2019000117A1 (hr) |
| TW (1) | TWI749091B (hr) |
| UA (1) | UA126910C2 (hr) |
| UY (1) | UY37459A (hr) |
| WO (1) | WO2018078064A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818917A (zh) | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| CN110964034B (zh) * | 2018-09-29 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 |
| AR116635A1 (es) * | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| TW202038960A (zh) | 2018-11-14 | 2020-11-01 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 |
| TW202114682A (zh) | 2019-06-17 | 2021-04-16 | 法商施維雅藥廠 | Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物 |
| WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
| EP4312536A1 (en) | 2021-04-01 | 2024-02-07 | Vestaron Corporation | Liposome formulations for pesticide delivery and methods for producing and using the same |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Ｍｃｌ－１抑制劑與抗體藥物接合物之組合 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| US20030044454A1 (en) | 1998-06-30 | 2003-03-06 | Masaru Fukui | Compositions containing liposomes and/or emulsions and process for the preparation thereof |
| DE60027730T2 (de) * | 1999-09-09 | 2007-03-29 | The Regents Of The University Of California, Oakland | Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen |
| KR20010100194A (ko) | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| JP2002080400A (ja) | 2000-06-23 | 2002-03-19 | Takeda Chem Ind Ltd | リン脂質含有薬物の製造法 |
| CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| ATE440593T1 (de) | 2001-03-27 | 2009-09-15 | Phares Pharm Res Nv | Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| WO2004069224A2 (en) | 2003-02-03 | 2004-08-19 | Neopharm, Inc. | Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
| JP2005075783A (ja) | 2003-09-01 | 2005-03-24 | Otsuka Pharmaceut Factory Inc | 難溶性化合物の可溶化または分散化用組成物 |
| JP2005225818A (ja) | 2004-02-13 | 2005-08-25 | Otsuka Pharmaceut Factory Inc | パクリタキセル又はドセタキセルの医薬組成物 |
| WO2008114274A1 (en) | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
| EP2344198B1 (en) | 2008-09-27 | 2020-11-04 | Jina Pharmaceuticals Inc. | Lipid based pharmaceutical preparations for topical application |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| SI2508170T1 (sl) | 2009-12-03 | 2015-12-31 | Jiangsu Hengrui Medicine Co., Ltd. | Liposom z irinotekanom ali njegovim hidrokloridom in njun postopek priprave |
| JP2012051823A (ja) | 2010-08-31 | 2012-03-15 | Fujifilm Corp | 難容性薬物含有水中油型乳化組成物及びその製造方法 |
| CN101926757B (zh) | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| EP2648698A1 (en) | 2010-12-08 | 2013-10-16 | F.Hoffmann-La Roche Ag | Liposomal formulation of dalcetrapib |
| WO2012118376A1 (en) | 2011-03-01 | 2012-09-07 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
| CN103622911B (zh) | 2013-11-19 | 2015-12-30 | 常州金远药业制造有限公司 | 一种难溶性药物脂质体制备方法 |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-10-27 SI SI201731200T patent/SI3532067T1/sl unknown
- 2017-10-27 UA UAA201905614A patent/UA126910C2/uk unknown
- 2017-10-27 DK DK17787939.2T patent/DK3532067T3/da active
- 2017-10-27 TW TW106137030A patent/TWI749091B/zh active
- 2017-10-27 IL IL266198A patent/IL266198B2/en unknown
- 2017-10-27 SG SG11201903326RA patent/SG11201903326RA/en unknown
- 2017-10-27 US US16/344,431 patent/US10722466B2/en active Active
- 2017-10-27 KR KR1020197015033A patent/KR102653436B1/ko active IP Right Grant
- 2017-10-27 BR BR112019008263A patent/BR112019008263A2/pt unknown
- 2017-10-27 TN TNP/2019/000117A patent/TN2019000117A1/en unknown
- 2017-10-27 ES ES17787939T patent/ES2923929T3/es active Active
- 2017-10-27 EA EA201991025A patent/EA201991025A1/ru unknown
- 2017-10-27 AU AU2017350499A patent/AU2017350499B2/en active Active
- 2017-10-27 EP EP17787939.2A patent/EP3532067B1/en active Active
- 2017-10-27 CA CA3041592A patent/CA3041592C/en active Active
- 2017-10-27 MY MYPI2019002297A patent/MY194730A/en unknown
- 2017-10-27 PT PT177879392T patent/PT3532067T/pt unknown
- 2017-10-27 MX MX2019004941A patent/MX2019004941A/es unknown
- 2017-10-27 HR HRP20220952TT patent/HRP20220952T1/hr unknown
- 2017-10-27 MA MA46608A patent/MA46608B1/fr unknown
- 2017-10-27 HU HUE17787939A patent/HUE059448T2/hu unknown
- 2017-10-27 PL PL17787939.2T patent/PL3532067T3/pl unknown
- 2017-10-27 RU RU2019115688A patent/RU2756755C2/ru active
- 2017-10-27 RS RS20220677A patent/RS63400B1/sr unknown
- 2017-10-27 JP JP2019522453A patent/JP7041676B2/ja active Active
- 2017-10-27 GE GEAP201715047A patent/GEP20217244B/en unknown
- 2017-10-27 AR ARP170102984A patent/AR109981A1/es unknown
- 2017-10-27 LT LTEPPCT/EP2017/077538T patent/LT3532067T/lt unknown
- 2017-10-27 WO PCT/EP2017/077538 patent/WO2018078064A1/en active Application Filing
- 2017-10-27 MD MDE20190973T patent/MD3532067T2/ro unknown
- 2017-10-27 CN CN201780067045.2A patent/CN109922808B/zh active Active
- 2017-10-27 UY UY0001037459A patent/UY37459A/es unknown
- 2017-10-27 CU CU2019000046A patent/CU20190046A7/es unknown
-
2019
- 2019-04-12 PH PH12019500804A patent/PH12019500804A1/en unknown
- 2019-04-26 CO CONC2019/0004190A patent/CO2019004190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220952T1 (hr) | Liposomalna formulacija za korištenje kod liječenja raka | |
| US11071713B2 (en) | Liposome composition | |
| AU2010227549B2 (en) | Pharmaceutical composition containing a drug and siRNA | |
| PT1443900E (pt) | Composições de veículo lipídico com estabilidade melhorada no sangue | |
| US11147881B2 (en) | Controlled drug release liposome compositions and methods thereof | |
| US20080107722A1 (en) | Method For Loading Multiple Agents Into Delivery Vehicles | |
| US20160030340A1 (en) | Controlled drug release liposome composition | |
| Trendowski et al. | Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration | |
| JP6705933B2 (ja) | リポソーム組成物およびその製造方法 | |
| ES2952680T3 (es) | Eribulina para inhibir el crecimiento tumoral | |
| WO2014184726A2 (en) | Compounds and their use in therapy | |
| US20240173257A1 (en) | Liposome formulations | |
| CN109077997B (zh) | 培美曲塞二钠脂质复合物及其制备方法 | |
| WO2021163466A1 (en) | Uses of hypoxia-inducible factor inhibtors for treating tp53-mutated acute myeloid leukemia | |
| JPH10505818A (ja) | リポソーム製剤 | |
| CN117897139A (zh) | Bcl抑制剂的脂质体制剂 | |
| JP2003221336A (ja) | 抗悪性腫瘍剤 |